Attached files
| file | filename |
|---|---|
| EX-99.2 - PRESENTATION FOR INVESTOR WEBCAST - SOLIGENIX, INC. | ea126656ex99-2_soligenix.htm |
| EX-99.1 - PRESS RELEASE OF SOLIGENIX, INC. DATED SEPTEMBER 10, 2020 - SOLIGENIX, INC. | ea126656ex99-1_soligenix.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): September 10, 2020
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as specified in its charter)
| Delaware | 41-1505029 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) | |
| 29 Emmons Drive, Suite B-10 Princeton, NJ |
08540 | |
| (Address of principal executive offices) |
(Zip Code) |
| (609) 538-8200 |
| (Issuer’s telephone number, including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value $.001 per share | SNGX | The Nasdaq Capital Market | ||
| Common Stock Purchase Warrants | SNGXW | The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On September 10, 2020, Soligenix, Inc. (the “Company”) issued a press release announcing an investor webcast regarding the advantages of the CiVax™ program for development of a broadly distributed heat stable COVID-19 vaccine. The development of CiVax™ is based on the thermostabilized glycoprotein vaccine platform which the Company, in collaboration with the University of Hawaiʻi at Mānoa, has been developing in connection with its multivalent thermostabilized vaccine candidates for filovirus infections, such as Ebola. The Company also released the presentation for the investor webcast.
The full text of the press release and the presentation for the investor webcast are filed as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press release of Soligenix, Inc. dated September 10, 2020. | |
| 99.2 | Presentation for Investor Webcast. |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Soligenix, Inc.
| ||
| September 10, 2020 | By: | /s/ Christopher J. Schaber |
|
Christopher J. Schaber, Ph.D. President and Chief Executive Officer (Principal Executive Officer) | ||
2